Clinical trialNCT06468202RecruitingPhase 4Interventional

Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

SponsorOhio State UniversityEnrollment10,742Gestational HypertensionHypertensive Disorders of PregnancyPreeclampsia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The overall goal of this large, pragmatic, comparative effectiveness trial is to test the hypothesis that among at-risk individuals, 162 mg/day aspirin is superior to 81 mg/day in preventing Hypertensive disorders of pregnancy (HDP), and that there are multiple factors associated with adherence with aspirin therapy that will be important to identify to enable optimal implementation of study findings and population-level benefits.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Denise Sholtens, PhD
Northwestern University Data Analysis and Coordinating Center
Principal Investigator
clinicaltrials.gov ↗
Maged Costantine, MD, MBA
Ohio State University
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham
Birmingham, Alabama, United States
Recruiting
Cedars Sinai Medical Center
Los Angeles, California, United States
Kimberly Gregory, MD, MPH
Recruiting
University of California, San Francisco
San Francisco, California, United States
Mary Norton, MD
Recruiting
Northwestern University
Chicago, Illinois, United States
Kiarri Kershaw, PhD, MPHMichelle Kominiarek, MD
Recruiting
University of Mississippi
Jackson, Mississippi, United States
Rachel Morris, MD
Recruiting
University of New Mexico
Albuquerque, New Mexico, United States
Christina Yarrington, MD
Recruiting
Columbia University
New York, New York, United States
Matthew Hoffman, MD
Recruiting
University of North Carolina, Chapel Hill
Chapel Hill, North Carolina, United States
Kim Boggess, MD
Recruiting
the Ohio State University Wexner Medical Center Ob/gyn Maternal and Fetal Medicine
Columbus, Ohio, United States
Ann McAlearney, ScD, MSAnne Trinh, MPHKara Rood, MD
Recruiting
University of Pittsburg Magee
Pittsburgh, Pennsylvania, United States
Hyagriv Simhan, MD
Recruiting
Brown University
Providence, Rhode Island, United States
Recruiting
University of Texas, Houston
Houston, Texas, United States
Baha Sibai, MD
Recruiting
University of Utah
Salt Lake City, Utah, United States
Recruiting
Inova Healthsystem
Falls Church, Virginia, United States
Recruiting
Eastern Virginia Medical School - Old Dominion University
Norfolk, Virginia, United States
George Saade, MD
Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Aspirin →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 18 Oct 2024
Primary completion: 1 Jan 2029
Completion: 1 Feb 2030
Last update posted: 4 May 2026
Registered enrollment: 10,742
Registry id: NCT06468202

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.